#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Anal cancer recurrent Cervix carcinoma recurrent Epilepsy with myoclonic-atonic seizures Ehlers-Danlos syndrome Haemophilia A without inhibitors Thermal burn Bone marrow disorder Ductal adenocarcinoma of pancreas Neurofibromatosis Bronchopulmonary dysplasia Endometrial cancer Congenital nephrogenic diabetes insipidus Non-Hodgkin's lymphoma unspecified histology aggressive recurrent Peritoneal mesothelioma malignant Oesophageal squamous cell carcinoma stage II More trials…

    Learn about Rare Diseases

    Progressive multifocal leukoencephalopathy – Diagnostics Short-bowel syndrome – Life with Disease Small intestine leiomyosarcoma – Trials in Disease Metachromatic leukodystrophy – Diagnostics Usher’s syndrome – Basic Information Paroxysmal nocturnal haemoglobinuria – Life with Disease Acquired haemophilia Aicardi-Goutieres syndrome – Trials in Disease Nephrotic syndrome – Diagnostics Congenital hypotransferrinaemia More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Namilumab Roxithromycin Tenofovir Disoproxil Fumarate Nitrous Oxide Neratinib Micronised Spironolactone Pentetic Acid Mezigdomide Antipsychotics Betamethasone Ioflupane (123I) Letermovir Birtamimab Epinephrine Tolu Balsam Cyclophosphamide Alpelisib Brodalumab Indocyanine Green Dabigatran More therapies…

    Learn about Your Condition

    Pharyngeal cancer stage II ROHHAD syndrome Pancreatic failure Metastatic neoplasm Oesophagectomy Retinal vein occlusion Hyperinsulinism End stage renal disease Rectal cancer Septic shock Anal cancer recurrent Wolfram syndrome Mantle cell lymphoma recurrent Rheumatic disorder Arteriovenous malformation More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Hospitalier Universitaire Amiens Picardie

Centre Hospitalier Universitaire Amiens Picardie

1 Place Victor Pauchet, Amiens, 80080, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study of Pucotenlimab with Becotatug Vedotin versus Becotatug Vedotin alone for patients with locally advanced head and neck squamous cell carcinoma

    Not recruiting

    2 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of head and neck
    Investigated Drugs:
    • PUCOTENLIMAB
    France

  • Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Gilteritinib
    • Midostaurin
    Austria Belgium Finland France Germany Ireland +5

  • Study Comparing Avelumab, Cetuximab, and Radiotherapy with Standard Treatments for Patients with Advanced Head and Neck Squamous Cell Carcinoma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Avelumab
    • Cetuximab
    • Cisplatin
    France

  • Study of Ivosidenib or Enasidenib with Chemotherapy for Patients with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with IDH1 or IDH2 Mutation

    Not recruiting

    3 1
    Investigated Drugs:
    • Enasidenib Mesilate
    • Ivosidenib
    Austria Belgium Estonia Finland France Germany +6

  • Study on Early Temozolomide Treatment for Adults with Glioblastoma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Glioblastoma multiforme
    • Glioblastoma
    Investigated Drugs:
    • Temozolomide
    Belgium France

  • Study of mRNA-4157 and Pembrolizumab for Patients with High-Risk Stage II-IV Melanoma

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Mrna-4157
    • Pembrolizumab
    Belgium Denmark France Germany Greece Italy +4

  • Study Comparing Pembrolizumab and Placebo for Patients with Resected High-Risk Stage II Melanoma

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Malignant melanoma
    Investigated Drugs:
    • Pembrolizumab
    Belgium France Germany Italy Poland Spain

  • Study Comparing Upadacitinib and Adalimumab for Adults with Moderate to Severe Rheumatoid Arthritis Not Responding to a Single TNF Inhibitor

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Adalimumab
    • Upadacitinib
    Belgium Bulgaria Croatia France Germany Greece +5

  • Study of Tafasitamab, Lenalidomide, and Rituximab for Patients with Relapsed or Refractory Follicular or Marginal Zone Lymphoma

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Lenalidomide
    • Rituximab
    • Tafasitamab
    Austria Belgium Czechia Denmark Finland France +10

  • Study on Baricitinib for Hospitalized Patients with Severe or Critical COVID-19

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Lung disorder
    Investigated Drugs:
    • Baricitinib
    Austria Belgium Czechia France Germany Greece +8
Previous Page
1 2 3 4
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!